# Ashland Inc.: financial statements, quarterly

ASH · NYSE · CIK 1674862 · [Consumer discretionary](/sectors/consumer-discretionary.md) · fiscal year ends Sep 30

Pages: [Overview](/companies/ash.md) · [Financials](/companies/ash/financials.md) · [Filings](/companies/ash/filings.md) · [Insiders](/companies/ash/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ash/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-09-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q4 FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [517 d](/filings/0001193125-25-289248.md) | [473](/filings/0000950170-25-010377.md) | [575](/filings/0000950170-25-061809.md) | [544](/filings/0000950170-25-100270.md) | [522 d](/filings/0001193125-25-289248.md) | [405](/filings/0001193125-26-035054.md) | [479](/filings/0001193125-26-191380.md) | [463](/filings/0001193125-26-324226.md) | [477 d](/filings/0001193125-25-289248.md) | [386](/filings/0001193125-26-035054.md) | [482](/filings/0001193125-26-191380.md) | [497](/filings/0001193125-26-324226.md) |
| Cost of revenue | $m | [389 d](/filings/0001193125-25-289248.md) | [375](/filings/0000950170-25-010377.md) | [414](/filings/0000950170-25-061809.md) | [358](/filings/0000950170-25-100270.md) | [348 d](/filings/0001193125-25-289248.md) | [294](/filings/0001193125-26-035054.md) | [332](/filings/0001193125-26-191380.md) | [331](/filings/0001193125-26-324226.md) | [318 d](/filings/0001193125-25-289248.md) | [281](/filings/0001193125-26-035054.md) | [335](/filings/0001193125-26-191380.md) | [327](/filings/0001193125-26-324226.md) |
| Gross profit | $m | [128 d](/filings/0001193125-25-289248.md) | [98.0](/filings/0000950170-25-010377.md) | [161](/filings/0000950170-25-061809.md) | [186](/filings/0000950170-25-100270.md) | [174 d](/filings/0001193125-25-289248.md) | [111](/filings/0001193125-26-035054.md) | [147](/filings/0001193125-26-191380.md) | [132](/filings/0001193125-26-324226.md) | [159 d](/filings/0001193125-25-289248.md) | [105](/filings/0001193125-26-035054.md) | [147](/filings/0001193125-26-191380.md) | [170](/filings/0001193125-26-324226.md) |
| Research and development | $m | [14.0 d](/filings/0001193125-25-289248.md) | [12.0](/filings/0000950170-25-010377.md) | [14.0](/filings/0000950170-25-061809.md) | [15.0](/filings/0000950170-25-100270.md) | [13.0 d](/filings/0001193125-25-289248.md) | [13.0](/filings/0001193125-26-035054.md) | [14.0](/filings/0001193125-26-191380.md) | [13.0](/filings/0001193125-26-324226.md) | [13.0 d](/filings/0001193125-25-289248.md) | [13.0](/filings/0001193125-26-035054.md) | [14.0](/filings/0001193125-26-191380.md) | [15.0](/filings/0001193125-26-324226.md) |
| Selling, general and administrative | $m | [109 d](/filings/0001193125-25-289248.md) | [83.0](/filings/0000950170-25-010377.md) | [106](/filings/0000950170-25-061809.md) | [114](/filings/0000950170-25-100270.md) | [101 d](/filings/0001193125-25-289248.md) | [78.0](/filings/0001193125-26-035054.md) | [85.0](/filings/0001193125-26-191380.md) | [106](/filings/0001193125-26-324226.md) | [76.0 d](/filings/0001193125-25-289248.md) | [86.0](/filings/0001193125-26-035054.md) | [79.0](/filings/0001193125-26-191380.md) | [99.0](/filings/0001193125-26-324226.md) |
| Operating income | $m | [(10.0) d](/filings/0001193125-25-289248.md) | [(18.0)](/filings/0000950170-25-010377.md) | [21.0](/filings/0000950170-25-061809.md) | [(61.0)](/filings/0000950170-25-100270.md) | [31.0 d](/filings/0001193125-25-289248.md) | [(179)](/filings/0001193125-26-035054.md) | [51.0](/filings/0001193125-26-191380.md) | [(708)](/filings/0001193125-26-324226.md) | [61.0 d](/filings/0001193125-25-289248.md) | [(6.0)](/filings/0001193125-26-035054.md) | [39.0](/filings/0001193125-26-191380.md) | [43.0](/filings/0001193125-26-324226.md) |
| Income tax | $m | [(29.0) d](/filings/0001193125-25-289248.md) | [(24.0)](/filings/0000950170-25-010377.md) | [(104)](/filings/0000950170-25-061809.md) | [(101)](/filings/0000950170-25-100270.md) | [6.0 d](/filings/0001193125-25-289248.md) | [(43.0)](/filings/0001193125-26-035054.md) | [9.0](/filings/0001193125-26-191380.md) | [15.0](/filings/0001193125-26-324226.md) | [32.0 d](/filings/0001193125-25-289248.md) | [(1.0)](/filings/0001193125-26-035054.md) | [5.0](/filings/0001193125-26-191380.md) | [15.0](/filings/0001193125-26-324226.md) |
| Net income | $m | [(4.0) d](/filings/0001193125-25-289248.md) | [26.0](/filings/0000950170-25-010377.md) | [120](/filings/0000950170-25-061809.md) | [6.0](/filings/0000950170-25-100270.md) | [16.0 d](/filings/0001193125-25-289248.md) | [(165)](/filings/0001193125-26-035054.md) | [31.0](/filings/0001193125-26-191380.md) | [(742)](/filings/0001193125-26-324226.md) | [32.0 d](/filings/0001193125-25-289248.md) | [(12.0)](/filings/0001193125-26-035054.md) | [16.0](/filings/0001193125-26-191380.md) | [16.0](/filings/0001193125-26-324226.md) |
| Diluted EPS | $ per share | not reported | [0.51](/filings/0000950170-25-010377.md) | [2.39](/filings/0000950170-25-061809.md) | [0.12](/filings/0000950170-25-100270.md) | not reported | [(3.50)](/filings/0001193125-26-035054.md) | [0.65](/filings/0001193125-26-191380.md) | [(16.21)](/filings/0001193125-26-324226.md) | not reported | [(0.26)](/filings/0001193125-26-035054.md) | [0.34](/filings/0001193125-26-191380.md) | [0.35](/filings/0001193125-26-324226.md) |
| Basic EPS | $ per share | not reported | [0.51](/filings/0000950170-25-010377.md) | [2.42](/filings/0000950170-25-061809.md) | [0.12](/filings/0000950170-25-100270.md) | not reported | [(3.50)](/filings/0001193125-26-035054.md) | [0.65](/filings/0001193125-26-191380.md) | [(16.21)](/filings/0001193125-26-324226.md) | not reported | [(0.26)](/filings/0001193125-26-035054.md) | [0.34](/filings/0001193125-26-191380.md) | [0.35](/filings/0001193125-26-324226.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:ProfitLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-09-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [417](/filings/0000950170-24-128009.md) | [440](/filings/0000950170-24-009280.md) | [439](/filings/0000950170-24-051148.md) | [399](/filings/0000950170-24-092587.md) | [300](/filings/0001193125-25-289248.md) | [219](/filings/0000950170-25-010377.md) | [168](/filings/0000950170-25-061809.md) | [207](/filings/0000950170-25-100270.md) | [215](/filings/0001193125-26-324226.md) | [304](/filings/0001193125-26-035054.md) | [343](/filings/0001193125-26-191380.md) | [440](/filings/0001193125-26-324226.md) |
| Current assets | $m | [1,506](/filings/0000950170-24-128009.md) | [1,365](/filings/0000950170-24-009280.md) | [1,427](/filings/0000950170-24-051148.md) | [1,385](/filings/0000950170-24-092587.md) | [1,195](/filings/0001193125-25-289248.md) | [1,069](/filings/0000950170-25-010377.md) | [1,075](/filings/0000950170-25-061809.md) | [1,124](/filings/0000950170-25-100270.md) | [1,205](/filings/0001193125-26-324226.md) | [1,154](/filings/0001193125-26-035054.md) | [1,209](/filings/0001193125-26-191380.md) | [1,292](/filings/0001193125-26-324226.md) |
| Total assets | $m | [5,939](/filings/0000950170-24-128009.md) | [5,866](/filings/0000950170-24-009280.md) | [5,948](/filings/0000950170-24-051148.md) | [5,747](/filings/0000950170-24-092587.md) | [5,645](/filings/0001193125-25-289248.md) | [5,231](/filings/0000950170-25-010377.md) | [5,233](/filings/0000950170-25-061809.md) | [4,621](/filings/0000950170-25-100270.md) | [4,611](/filings/0001193125-26-324226.md) | [4,519](/filings/0001193125-26-035054.md) | [4,499](/filings/0001193125-26-191380.md) | [4,578](/filings/0001193125-26-324226.md) |
| Current liabilities | $m | [456](/filings/0000950170-24-128009.md) | [414](/filings/0000950170-24-009280.md) | [453](/filings/0000950170-24-051148.md) | [464](/filings/0000950170-24-092587.md) | [490](/filings/0001193125-25-289248.md) | [425](/filings/0000950170-25-010377.md) | [463](/filings/0000950170-25-061809.md) | [420](/filings/0000950170-25-100270.md) | [423](/filings/0001193125-26-324226.md) | [366](/filings/0001193125-26-035054.md) | [395](/filings/0001193125-26-191380.md) | [424](/filings/0001193125-26-324226.md) |
| Long-term debt | $m | [1,314](/filings/0000950170-24-128009.md) | [1,341](/filings/0000950170-24-009280.md) | [1,328](/filings/0000950170-24-051148.md) | [1,325](/filings/0000950170-24-092587.md) | [1,349](/filings/0001193125-25-289248.md) | [1,313](/filings/0000950170-25-010377.md) | [1,336](/filings/0000950170-25-061809.md) | [1,382](/filings/0000950170-25-100270.md) | [1,384](/filings/0001193125-26-324226.md) | [1,387](/filings/0001193125-26-035054.md) | [1,374](/filings/0001193125-26-191380.md) | [1,374](/filings/0001193125-26-324226.md) |
| Current portion of debt | $m | [0.0](/filings/0001193125-25-289248.md) | [0.0](/filings/0000950170-24-009280.md) | [0.0](/filings/0000950170-24-051148.md) | [0.0](/filings/0000950170-24-092587.md) | [0.0](/filings/0001193125-25-289248.md) | not reported | not reported | [0.0](/filings/0000950170-25-100270.md) | [0.0](/filings/0001193125-26-324226.md) | [0.0](/filings/0001193125-26-035054.md) | [0.0](/filings/0001193125-26-191380.md) | [0.0](/filings/0001193125-26-324226.md) |
| Short-term borrowings | $m | [16.0](/filings/0000950170-24-128009.md) | [0.0](/filings/0000950170-24-009280.md) | [0.0](/filings/0000950170-24-051148.md) | [0.0](/filings/0000950170-24-092587.md) | [0.0](/filings/0000950170-25-061809.md) | not reported | [50.0](/filings/0000950170-25-061809.md) | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [3,097](/filings/0000950170-24-128009.md) | [3,053](/filings/0000950170-24-009280.md) | [3,134](/filings/0000950170-25-061809.md) | [2,967](/filings/0000950170-25-100270.md) | [2,868](/filings/0001193125-25-289248.md) | [2,592](/filings/0001193125-26-035054.md) | [2,559](/filings/0001193125-26-191380.md) | [1,889](/filings/0001193125-26-324226.md) | [1,904](/filings/0001193125-26-324226.md) | [1,878](/filings/0001193125-26-035054.md) | [1,866](/filings/0001193125-26-191380.md) | [1,870](/filings/0001193125-26-324226.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-09-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q4 FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [131 d](/filings/0001193125-25-289248.md) | [201](/filings/0000950170-25-010377.md) | [54.0 d](/filings/0000950170-25-061809.md) | [127 d](/filings/0000950170-25-100270.md) | [80.0 d](/filings/0001193125-25-289248.md) | [(30.0)](/filings/0001193125-26-035054.md) | [9.0 d](/filings/0001193125-26-191380.md) | [115 d](/filings/0001193125-26-324226.md) | [40.0 d](/filings/0001193125-25-289248.md) | [125](/filings/0001193125-26-035054.md) | [50.0 d](/filings/0001193125-26-191380.md) | [120 d](/filings/0001193125-26-324226.md) |
| Capital expenditure | $m | [69.0 d](/filings/0001193125-25-289248.md) | [36.0](/filings/0000950170-25-010377.md) | [34.0 d](/filings/0000950170-25-061809.md) | [29.0 d](/filings/0000950170-25-100270.md) | [38.0 d](/filings/0001193125-25-289248.md) | [23.0](/filings/0001193125-26-035054.md) | [21.0 d](/filings/0001193125-26-191380.md) | [20.0 d](/filings/0001193125-26-324226.md) | [34.0 d](/filings/0001193125-25-289248.md) | [14.0](/filings/0001193125-26-035054.md) | [17.0 d](/filings/0001193125-26-191380.md) | [20.0 d](/filings/0001193125-26-324226.md) |
| Dividends paid | $m | [20.0 d](/filings/0001193125-25-289248.md) | [20.0](/filings/0000950170-25-010377.md) | [19.0 d](/filings/0000950170-25-061809.md) | [20.0 d](/filings/0000950170-25-100270.md) | [19.0 d](/filings/0001193125-25-289248.md) | [19.0](/filings/0001193125-26-035054.md) | [19.0 d](/filings/0001193125-26-191380.md) | [19.0 d](/filings/0001193125-26-324226.md) | [19.0 d](/filings/0001193125-25-289248.md) | [19.0](/filings/0001193125-26-035054.md) | [19.0 d](/filings/0001193125-26-191380.md) | [19.0 d](/filings/0001193125-26-324226.md) |
| Share repurchases | $m | [0.0 d](/filings/0001193125-25-289248.md) | [100](/filings/0000950170-25-010377.md) | [0.0 d](/filings/0000950170-25-061809.md) | [130 d](/filings/0000950170-25-100270.md) | [150 d](/filings/0001193125-25-289248.md) | [0.0](/filings/0000950170-25-010377.md) | [100 d](/filings/0001193125-26-191380.md) | [0.0 d](/filings/0001193125-26-324226.md) | [0.0 d](/filings/0001193125-25-289248.md) | not reported | not reported | [0.0 d](/filings/0001193125-26-324226.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q1 FY2023 (2022-12-31) | Q2 FY2023 (2023-03-31) | Q3 FY2023 (2023-06-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [55.0](/filings/0000950170-24-009280.md) | [55.0](/filings/0000950170-24-051148.md) | [53.0](/filings/0000950170-24-092587.md) | [51.0](/filings/0000950170-25-010377.md) | [51.0](/filings/0000950170-25-061809.md) | [51.0](/filings/0000950170-25-100270.md) | [0.0](/filings/0001193125-26-035054.md) | [0.0](/filings/0001193125-26-191380.md) | [0.0](/filings/0001193125-26-324226.md) | [0.0](/filings/0001193125-26-035054.md) | [0.0](/filings/0001193125-26-191380.md) | [0.0](/filings/0001193125-26-324226.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 45,793,370 at 2026-06-30, from the cover of the [10-Q filed 2026-07-29](/filings/0001193125-26-324226.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.